Background

Current vaccine platforms have mixed success at preventing infection of new emerging infectious diseases and present several limitations. To overcome those limitations researchers at St George’s, University of London have developed a protein-only based vaccine that is delivered via a respiratory route and generates robust mucosal immunity.

The development of a vaccine platform that creates an immune response in the lungs and the upper respiratory tract is important for protection against respiratory pathogens like the SARS-CoV2, which is causing the Covid-19 pandemic. And due to the increasing threat of new variants of the virus, not only a refinement of the current approaches is needed, but also entirely new and more effective preventive strategies.

As of today, there is no